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Th e search for a biochemical marker that can be used to 
conﬁ rm infection and sepsis – much like troponin is used 
to diagnose myocardial injury [1] – has been the source 
of a great deal of work. Many diﬀ erent compounds have 
been assessed either to diagnose the condition or to 
prog nos ticate between a good and a poor outcome in 
patients in whom the problem has already been 
diagnosed. Th ese include acute-phase proteins such as C-
reactive protein [2], procalcitonin, inﬂ ammatory (pro- 
and anti-) cyto kines, cell surface proteins (adhesion 
molecules, for instance), and markers of coagulation and 
apoptosis [3].
Th e ideal biomarker should possess a number of 
properties: it should have a high sensitivity for the disease 
process being detected, it should be very speciﬁ c (that is, 
it should not be present if the disease is absent), its levels 
should reﬂ ect the severity of the condition, it should have 
a time course that allows the clinical evolution of the 
disease to be detected early, it should have a half-life that 
enables raised levels to remain in a clinically useful time 
frame and then decrease  to enable tracking of severity, it 
should provide independent information on outcome, 
and it should be reproducible and, of course, cheap and 
easy to measure. Very few of the available bio markers 
possess all of these qualities. If an ideal bio marker were 
found, however, we would have a tool that would help us 
to diagnose sepsis early and, in turn, enable us to direct 
evidence-based interventions directly toward the 
appropriate groups. In addition, this biomarker would 
enable clinical trials to be performed on homogenous 
patient groups of a comparable risk severity and, in turn, 
improve patient selection and therefore hopefully 
increase the likelihood of positive (or negative) results.
In recent years,  free circulating nucleic acids in plasma 
and serum have been studied as biomarkers [4]. Free 
circulat ing DNA – cell-free DNA (cfDNA) – is released 
from a number of cells, including neutrophils, eosino-
phils, and macrophages, as a result of either apoptosis or 
other forms of cellular damage [5]. A couple of important 
considerations have to be made in order to understand 
the possible clinical impact of this biomarker. First, levels 
of cfDNA are detectable in healthy individuals; second, 
raised levels are not speciﬁ c to a single disease. 
Nevertheless, raised levels of cfDNA have been shown, in 
a number of studies, to be extremely sensitive and 
speciﬁ c for poor outcomes. cfDNA has been shown to 
have prognostic relevance in many conditions, including 
trauma [6], stroke [7], cancer, diabetes mellitus, sickle cell 
disease, organ transplantation [4], and critical illness 
[8-10].
In the previous issue of Critical Care, Dwivedi et al. 
[11] conﬁ rmed the prognostic abilities of cfDNA in 
severe sepsis. In a retrospective observational study of 80 
patients with severe sepsis, the authors were able to show 
that cfDNA at baseline had a remarkable discriminatory 
power to predict intensive care mortality and, to a lesser 
(though still impressive) extent, hospital mortality. 
cfDNA performed a lot better than any of the available 
severity of illness or organ dysfunction scoring systems 
and also a lot better than interleukin-6, thrombin, and 
protein C. Indeed, the addition of these other markers 
added very little to the overall results. A cutoﬀ  level of 
cfDNA at baseline of 2.35 ng/μL had a sensitivity of 88% 
and a speciﬁ city of 94% for predicting intensive care unit 
mortality.
At least in terms of prediction in intensive care, these 
results are very similar to those of studies by Rhodes et 
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al. [8], Butt et al. [9], and Saukkonen et al. [10] in mixed 
critical illness and sepsis and by Lo et al. [6] in trauma. In 
each of these studies, the presence of increased levels of 
this marker had very signiﬁ cant abilities to predict overall 
outcome from the disease being treated. Another thing 
these studies have in common, however, is that they are 
all on relatively small samples of patients, and it is 
gratifying to see that Dwivedi et al. already have a grant 
to complete a larger conﬁ rmatory study. We await the 
results eagerly.
Several questions do need to be considered, however. 
Raised levels have been detected in a number of diﬀ erent 
diseases [12] and interventions (for instance, hemo-
dialysis [13]) that are all too often present in patients with 
sepsis. Which of the two are leading to the raised levels 
or the sepsis per se: the underpinning diseases or the 
interventions? In addition, what is the additive eﬀ ect of 
the interventions on a complicated patient requiring 
multiple organ supports? In a separate issue, the fact that 
the results suggest that outcome can be predicted at 
baseline does raise an important concern. Does this mean 
that, if cfDNA is already elevated when we start to treat 
these patients, the chances of survival will not be aﬀ ected 
by our treatment? Or even worse, does it mean that some 
patients already have a predetermined outcome when 
they present to us for treatment? If so, what is the eﬀ ect 
of our current managements and supports? If this is the 
case, then the implications for how the information 
would be used are profound.
In the studies performed to date, circulating cell-free 
nucleic acids seem to be among the more promising 
prognostic markers that could be used in severe sepsis. 
Th e studies do need replicating, however, and the assays 
need standardizing and would need to be made more 
user-friendly. Only then could we consider measuring 
this as a routine in our patients, and even then, we would 
need some careful thoughts about how to act upon the 
information obtained. Th is new information would 
enable better selection for clinical trials but also may 
have a far wider potential as a routine part of our clinical 
investigation and management.
Abbreviation
cfDNA, cell-free DNA.
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